Next Science Yönetim

Yönetim kriter kontrolleri 0/4

Next Science CEO'su I.V. Hall, Jul2023 tarihinde atandı, in görev süresi 1.5 yıldır. in toplam yıllık tazminatı $ 418.38K olup, şirket hissesi ve opsiyonları dahil olmak üzere 47.6% maaş ve 52.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.23% ine doğrudan sahiptir ve bu hisseler A$ 73.16K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.7 yıl ve 1.5 yıldır.

Anahtar bilgiler

I.V. Hall

İcra Kurulu Başkanı

US$418.4k

Toplam tazminat

CEO maaş yüzdesi	47.6%
CEO görev süresi	1.5yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	1.7yrs
Yönetim Kurulu ortalama görev süresi	1.5yrs

Son yönetim güncellemeleri

Recent updates

Even With A 26% Surge, Cautious Investors Are Not Rewarding Next Science Limited's (ASX:NXS) Performance Completely

Jan 22

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 36% Cheaper

Oct 22

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 29% Bounce

Jul 26

It's Down 32% But Next Science Limited (ASX:NXS) Could Be Riskier Than It Looks

Jun 08

Will Next Science (ASX:NXS) Spend Its Cash Wisely?

Apr 16

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 26% Bounce

Mar 06

Potential Upside For Next Science Limited (ASX:NXS) Not Without Risk

Dec 26

Next Science Limited (ASX:NXS) Analysts Just Trimmed Their Revenue Forecasts By 10%

Oct 26

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 26% Cheaper

May 13

The Next Science Limited (ASX:NXS) Analysts Have Been Trimming Their Sales Forecasts

Feb 03

Here's Why We're Not Too Worried About Next Science's (ASX:NXS) Cash Burn Situation

Jan 25

What Type Of Returns Would Next Science's(ASX:NXS) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Nov 23

CEO Tazminat Analizi

I.V. Hall'un ücretlendirmesi Next Science'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$418k	US$199k	-US$16m

Tazminat ve Piyasa: I.V. 'nin toplam tazminatı ($USD 418.38K ), Australian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 283.80K ).

Tazminat ve Kazançlar: I.V. şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

I.V. Hall

1.5yrs

Görev süresi

US$418,378

Tazminat

Mr. Harry Thomas Hall, IV, also known as I.V., has been Managing Director and Chief Executive Officer at Next Science Limited since July 10, 2023. He serves as Director at Next Science Limited since July 1...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Harry Hall	MD, CEO & Director	1.5yrs	US$418.38k	0.23% A$ 73.2k
Matthew Myntti	Founder & CTO	no data	US$413.71k	1.43% A$ 458.9k
Marc Zimmerman	Chief Financial Officer	1.7yrs	US$343.34k	0.051% A$ 16.5k
Jon Swanson	Chief Operating Officer	6.6yrs	US$298.60k	0.017% A$ 5.5k
Francoise Dixon	Head of Investor Relations	no data	Veri yok	Veri yok
Robert Bell	Senior Vice President of North American Sales	1yr	Veri yok	Veri yok
Gillian Nairn	Company Secretary	6.6yrs	Veri yok	Veri yok

1.7yrs

Ortalama Görev Süresi

Deneyimli Yönetim: NXS 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Harry Hall	MD, CEO & Director	1.5yrs	US$418.38k	0.23% A$ 73.2k
Grant Hummel	Independent Non-Executive Director	1.4yrs	US$21.45k	0.13% A$ 42.6k
Aileen Stockburger	Independent Non-Executive Chairman	6.3yrs	US$111.85k	0.19% A$ 62.7k
Katherine Ostin	Independent Non-Executive Director	1.3yrs	US$12.66k	Veri yok

1.5yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: NXS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.5 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/31 14:37
Gün Sonu Hisse Fiyatı	2025/01/31 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Next Science Limited 4 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Elyse Shapiro	Bell Potter
Martyn Jacobs	Canaccord Genuity
Dr Benson	Wilsons Advisory and Stockbroking Ltd.

Next Science Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Next Science Limited, Annual General Meeting, May 03, 2024

Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive Director

Next Science Limited Announces Board Changes

Next Science Limited Appoints Marc Zimmerman as Chief Financial Officer

Next Science Limited Announces Executive Changes

Founder & CTO recently sold AU$1.5m worth of stock

Recent updates

Even With A 26% Surge, Cautious Investors Are Not Rewarding Next Science Limited's (ASX:NXS) Performance Completely

Next Science Limited to Report Q4, 2024 Results on Jan 23, 2025

Next Science Limited and Next Science LLC Provide Update on Litigation Involving Former Employee

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 36% Cheaper

Next Science Limited to Report Q3, 2024 Results on Oct 22, 2024

Consensus EPS estimates fall by 11%

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 29% Bounce

Next Science Limited to Report First Half, 2024 Results on Aug 30, 2024

Next Science Limited to Report Q2, 2024 Results on Jul 25, 2024

It's Down 32% But Next Science Limited (ASX:NXS) Could Be Riskier Than It Looks

New minor risk - Share price stability

Next Science Limited to Report Q1, 2024 Results on Apr 24, 2024

Will Next Science (ASX:NXS) Spend Its Cash Wisely?

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 26% Bounce

Next Science Limited, Annual General Meeting, May 03, 2024

Full year 2023 earnings released: US$0.069 loss per share (vs US$0.06 loss in FY 2022)

Next Science Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

Potential Upside For Next Science Limited (ASX:NXS) Not Without Risk

Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million.

Next Science Limited (ASX:NXS) Analysts Just Trimmed Their Revenue Forecasts By 10%

Consensus revenue estimates decrease by 10%

Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive Director

Consensus revenue estimates increase by 26%, EPS downgraded

New minor risk - Shareholder dilution

First half 2023 earnings released: US$0.04 loss per share (vs US$0.032 loss in 1H 2022)

New minor risk - Financial data availability

Next Science Limited Announces Board Changes

Next Science Limited Appoints Marc Zimmerman as Chief Financial Officer

New minor risk - Share price stability

Next Science Limited Commercialising Its Proprietary Xbiotm Suite of Products

Next Science Limited Announces Executive Changes

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 26% Cheaper

Founder & CTO recently sold AU$1.5m worth of stock

Consensus EPS estimates fall from profit to US$0.051 loss, revenue upgraded

Full year 2022 earnings released: US$0.06 loss per share (vs US$0.047 loss in FY 2021)

Next Science Limited, Annual General Meeting, May 26, 2023

The Next Science Limited (ASX:NXS) Analysts Have Been Trimming Their Sales Forecasts

Forecast breakeven date pushed back to 2024

Next Science Limited announced that it expects to receive AUD 10 million in funding from Walker Group Holdings Pty Limited

Insufficient new directors

Next Science Limited Announces the Launch of Topical Collagen Products

Next Science Limited Announces Health Canada Given Licensing Approval for XPERIENCE

First half 2022 earnings released: US$0.032 loss per share (vs US$0.021 loss in 1H 2021)

Forecast breakeven date pushed back to 2024

Next Science Limited to Report First Half, 2022 Results on Aug 25, 2022

Consensus forecasts updated

Next Science Limited's Judith Mitchell to Step Down as Chief Executive Officer

Insufficient new directors

MD, CEO & Executive Director recently sold AU$123k worth of stock

Next Science Limited, Annual General Meeting, May 27, 2022

Forecast to breakeven in 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're Not Too Worried About Next Science's (ASX:NXS) Cash Burn Situation

Insufficient new directors

Founder & CTO recently sold AU$8.6m worth of stock

First half 2021 earnings released: US$0.021 loss per share (vs US$0.037 loss in 1H 2020)

Next Science Limited Agrees to Open Negotiations with Zimmer, Inc

Next Science Limited Provides Revenue Guidance for the First Half of 2021

Next Science Limited Receives Approval for BlastX from Therapeutic Goods Administration for Sale in Australia

Independent Non-Executive Chairman George Savvides has left the company

Next Science’s XPERIENCE No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA

Next Science Limited Announces XPerience No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA

Independent Non-Executive Director recently sold AU$564k worth of stock

MD, CEO & Executive Director exercised options to buy AU$2.5m worth of stock.

Full year 2020 earnings released: US$0.064 loss per share (vs US$0.086 loss in FY 2019)

Next Science Limited (ASX:NXS) Is Expected To Breakeven In The Near Future

Next Science Limited, Annual General Meeting, May 05, 2021

Analysts update estimates

Full year 2020 earnings released: US$0.064 loss per share (vs US$0.086 loss in FY 2019)